Award
National Institute of Allergy and Infectious Diseases 1R01AI202713-01
Development of a Novel Trivalent Adjuvanted TB Vaccine
Recipient
Not specified
Award Amount
$1,296,750.00
Ceiling
$1,296,750.00
Awarded
July 31, 2026
Identifier
1R01AI202713-01
Award for developing and evaluating a novel trivalent TB vaccine, funded by NIAID for about $1.3 million over 5 years.
Description
This project involves developing a novel trivalent TB vaccine, evaluating its efficacy and immune response in mice, and preparing for clinical development. The funding is provided by NIAID, with a total award amount of approximately $1.3 million for a 5-year period.